A Phase 1, Randomized, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Single or Multiple Subcutaneous Doses of Lyophilized Formulation of Recifercept in Healthy Participants
Latest Information Update: 12 Jan 2022
At a glance
- Drugs Recifercept (Primary)
- Indications Achondroplasia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 06 Jan 2022 Status changed from active, no longer recruiting to completed.
- 12 Oct 2021 Planned End Date changed from 20 Sep 2021 to 29 Oct 2021.
- 13 Sep 2021 Planned End Date changed from 20 Apr 2021 to 20 Sep 2021.